← Back to patent-cliff list
Enitociclib
Tier C — Watch / tradeEnitociclib
Bayer
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CDK9, PTEFb
Indications (approved)：Non-Hodgkin lymphoma, Lymphoma, Haematological malignancy, Neoplasm, 里氏综合征, Chronic lymphocytic leukaemia
Regional status
US
Phase II
2023-04-05
EU
Discontinued
2016-02-10
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Enitociclib?
Approved indications include: Non-Hodgkin lymphoma, Lymphoma, Haematological malignancy, Neoplasm, 里氏综合征, Chronic lymphocytic leukaemia.
When does the Enitociclib patent expire?
No public expiry year is available for Enitociclib yet; this page updates once verified.
How do I get a quote for Enitociclib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03